Industry

ROP treatment receives orphan drug designation

Healio Optometry15h ago1 min read

The FDA granted orphan drug designation to a triggering receptor expressed on myeloid cells 1 peptide inhibitor for the treatment of retinopathy of prematurity, according to a press release from SignaBlok.“Current therapeutic options (eye surgery, laser photocoagulation and eye injections of anti-VEGF drugs) are harmful, do not cure, have a high risk of serious complications and are often ineffective, suggesting an unmet need for new therapies,” Alexander B. Sigalov, PhD, president and founder of SignaBlok, told Healio. “SignaBlok addresses this urgent unmet need by introducing a novel,

Read full article on Healio Optometry

AI Summary

Quick Take

The FDA has granted orphan drug designation to SignaBlok’s novel TREM-1 peptide inhibitor for the treatment of retinopathy of prematurity (ROP). This peptide inhibitor targets the triggering receptor expressed on myeloid cells 1, offering a potential new pathway for treating a condition that currently relies on more invasive or systemic-risk-heavy interventions.

Why It Matters

Current ROP management relies heavily on laser photocoagulation and anti-VEGF injections, both of which carry significant baggage: laser causes permanent peripheral vision loss, and anti-VEGF agents raise concerns regarding systemic suppression of growth factors in developing neonates. SignaBlok’s approach suggests a shift toward modulating myeloid cell activity rather than just inhibiting vascular growth factors. If this peptide inhibitor proves effective, it could address a critical gap for infants who are non-responsive to current therapies or at high risk for traditional treatment complications.

Key Details

The drug is a peptide inhibitor of triggering receptor expressed on myeloid cells 1 (TREM-1).
Orphan drug designation was granted by the FDA to support the development of therapies for rare pediatric diseases.
The developer, SignaBlok, identifies current standards—including surgery, laser, and anti-VEGF—as potentially harmful or ineffective for some patients.
The therapy is being positioned as a novel alternative to address the 'urgent unmet need' in neonatal retinal care.

Practice Implications

While this designation is an early regulatory step, it signals a move toward more targeted molecular therapies for ROP. Clinicians should stay informed on upcoming clinical trial data for TREM-1 inhibitors, as they may eventually provide a treatment option with a different safety profile than current anti-VEGF protocols.

Who's Affected

Pediatric OphthalmologistsRetina SpecialistsNeonatologistsPediatric Optometrists

Evidence StrengthPreliminary

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.